Two pieces of evidence about citicoline and depression point in opposite directions, and both are worth knowing about before anyone decides the question is settled. One is a small randomized trial that found a clear benefit. The other is the largest network meta-analysis of nutraceuticals in depression ever published, which singled citicoline out for a problem.
Nothing here is medical advice. Citicoline is not approved by the FDA to diagnose, treat, cure, or prevent depression. Depression is a serious medical condition, and decisions about antidepressant treatment belong with the clinician managing it.
Key Takeaways
- A 2017 randomized, double-blind trial added citicoline 100 mg twice daily or placebo to citalopram in 50 patients with major depressive disorder for six weeks[1]
- Depression scores improved significantly more on citicoline at weeks 2, 4 and 6, and the remission rate was significantly higher[1]
- The dose was 200 mg per day, below a standard 500 mg capsule and far below the 2000 mg used in other psychiatric trials[1]
- A 2026 network meta-analysis of 163 studies and 15,757 participants found citicoline was associated with significantly more dropouts than placebo[2]
- In that analysis the compounds that outperformed placebo on depressive symptoms after quality filtering were EPA, vitamin D3 and a St John’s wort extract. Citicoline was not among them[2]
- Overall confidence in the nutraceutical depression evidence was rated low to very low[2]
The positive trial
Fifty patients with major depressive disorder, all already being treated with citalopram, were randomized to receive either citicoline at 100 mg twice a day or placebo as an adjuvant treatment for six weeks. Depressive symptoms were assessed with the Hamilton Depression Rating Scale at baseline and again at weeks 2, 4 and 6[1].
The citicoline group showed significantly greater improvement at every assessment point, with p values of 0.030, 0.032 and 0.021 respectively. A repeated-measures general linear model found a significant time by treatment interaction on the depression score, and the remission rate was significantly higher in the citicoline group at p = 0.045[1].
The authors concluded that citicoline was an effective adjuvant to citalopram in the therapy of major depressive disorder[1].
Why the dose is the most surprising detail
Almost every other psychiatric trial of citicoline used a much larger amount. The methamphetamine and cocaine work used 1000 to 2000 mg per day[3][4]. This trial used 200 mg per day in total, which is less than half of the smallest commonly sold capsule.
Two readings are possible. Either the effective dose for a mood outcome is genuinely far lower than for a cognitive or drug-use outcome, which would be a useful thing to know, or a small trial produced a result that a larger one would not reproduce. Nothing in the published record distinguishes them, and no replication at that dose exists.
It is at least a reason to be skeptical of anyone recommending a large dose on the strength of this study, since a large dose is not what this study tested. Our dosage guide covers the range that has actually been studied for other endpoints.
The 2026 network meta-analysis, and the dropout finding
In 2026, Molecular Psychiatry published a systematic review and network meta-analysis of nutraceuticals and phytoceuticals in major depressive disorder, covering 163 studies and 15,757 participants across 137 distinct compound combinations. Its co-primary outcomes were change in depressive symptoms, treatment response, and all-cause discontinuation as a measure of acceptability[2].
Its headline finding was a caution about the field rather than an endorsement of it. When the analysis was restricted to compounds with at least two trials, excluding comparisons against active antidepressants, and limited to low risk-of-bias and non-sponsored trials, the effect sizes that survived were for eicosapentaenoic acid, vitamin D3, and a specific St John’s wort extract. A meta-regression showed larger effect sizes were associated with lower methodological quality scores, and confidence in the evidence overall was rated low to very low[2].
Citicoline appears in that analysis in one place, and it is the acceptability outcome: citicoline was associated with significantly more dropouts than placebo[2].
What the dropout finding does and does not say
This deserves careful handling, because it is easy to turn into a claim the source does not make.
All-cause discontinuation counts everyone who left the trial for any reason. Side effects are one reason. So are lack of perceived benefit, inconvenience, moving away, and losing interest. The published abstract reports the discontinuation result without reporting the reasons behind it, so anyone who tells you this analysis showed citicoline causes intolerable side effects is going beyond what the record contains.
What it does say is meaningful anyway. Acceptability is a real outcome. A treatment people stop taking is not a useful treatment, whatever the mechanism of the stopping. And it is a notably different signal from the methamphetamine trial, where retention on citicoline was significantly better than placebo[3].
Both findings are in the literature. Our page on citicoline side effects covers the tolerability record separately, which is generally good in the individual trials.
How to hold two contradictory results at once
The honest position is that a single 50-person trial and a 163-study network meta-analysis are not the same weight of evidence, and the larger one does not support citicoline as an antidepressant.
That does not make the 2017 trial worthless. It was randomized, double-blind, placebo-controlled, and it measured a real outcome at three time points. It is exactly the kind of result that justifies a larger replication, which is what the field has not yet done.
A 2026 systematic review looking specifically at citicoline in mental disorders reached the same place from a different direction, finding results in mood disorders mixed, methodological quality limited, and concluding that these compounds belong in the adjunctive or investigational category rather than the evidence-based one[5].
What follows practically
If you are being treated for depression, the relevant fact is that every positive trial here tested citicoline added to a prescribed antidepressant. None tested it as a substitute, and none would support using it as one.
Adding a supplement to an SSRI is a conversation with a prescriber, not a purchase decision. There are interaction and monitoring reasons for that which have nothing to do with whether the supplement works, and our page on citicoline drug interactions covers the general considerations.
And if the deciding factor for you is the strength of the evidence rather than the plausibility of the mechanism, the network meta-analysis is the more informative document of the two. It is the one built to compare compounds against each other, and it did not put citicoline near the top.
Frequently Asked Questions
Does citicoline help depression?
One small randomized trial found that adding citicoline to citalopram improved Hamilton Depression Rating Scale scores and remission rates more than adding placebo. It has not been replicated, and larger evidence syntheses do not list citicoline among the compounds that survived quality filtering.
What dose did the positive trial use?
100 mg twice a day, so 200 mg total. That is notably lower than the 500 mg to 2000 mg used in most citicoline research and lower than a single standard capsule.
What did the 2026 network meta-analysis find?
Across 163 studies and 15,757 participants it found that citicoline was associated with significantly more dropouts than placebo. The compounds that outperformed placebo on depressive symptoms after quality filtering were EPA, vitamin D3 and a St John’s wort extract, not citicoline.
Does more dropouts mean side effects?
Not necessarily. The reported outcome is all-cause discontinuation, which the analysis treats as acceptability. The published abstract does not say why participants left, so the reason cannot be determined from that record.
Should I add citicoline to my antidepressant?
That is a decision for the prescriber who manages your treatment, not one to make from an article. Adding anything to an SSRI has interaction and monitoring implications, and the evidence here is one 50-person trial against an acceptability signal in a much larger analysis.
Is citicoline an antidepressant?
No. It is a dietary supplement in the United States and is not approved to treat depression. Every positive trial tested it as an addition to real antidepressant treatment, never as a replacement for one.
References
- Roohi-Azizi M, et al. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Neuropharmacol (2017). PMID 28085707
- Fornaro M, et al. Nutraceuticals and phytoceuticals for the treatment of major depressive disorder: a systematic review and network meta-analysis. Mol Psychiatry (2026). PMID 42680855
- Brown ES, Gorman AR. A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord (2012). PMID 22974472
- Brown ES, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder. Am J Psychiatry (2015). PMID 25998279
- Kucuksahin NG, et al. The Impact of Citicoline/Phosphatidylserine Supplementation on Cognitive Performance and Executive Functions in Mental Disorders: A Systematic Review of Controlled Trials. Hum Psychopharmacol (2026). PMID 42538853
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
